{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:47:59Z","timestamp":1792165679228,"version":"4.4.0"},"reference-count":75,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Precision dosing integrates patient-specific factors to optimize pharmacotherapy. However, current evidence often relies on limited single-center studies, restricting generalizability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A narrative review of literature on real-world evidence, pharmacogenetics, biomarkers, artificial intelligence (AI), and privacy-preserving data strategies relevant to precision dosing was conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Single-center data are insufficient for robust precision-dosing evidence because of small subgroups and local practice biases. Multicenter privacy-preserving systems enable richer, more generalizable datasets that link doses, exposures, genotypes, biomarkers, and outcomes. However, multicenter collaborations should remain aligned with the intended population and should not imply indiscriminate pooling of heterogeneous data. Secure pooled environments, federated learning, and synthetic data play distinct method-dependent roles. AI supports exposure estimation, phenotype extraction, and modeling of complex relationships but requires rigorous validation against conventional methods. Causal inference requires epidemiological rigor beyond predictive performance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Advancing precision dosing requires multicenter, purpose-specific, privacy-preserving, methodologically rigorous, and clinically validated data systems guided by clinical pharmacologists, with AI serving as a complementary tool rather than a default solution.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001534","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:00:15Z","timestamp":1792162815000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Integrating Artificial Intelligence and Multicenter Real-World Evidence to Advance Precision Dosing: A Critical Perspective Review"],"prefix":"10.1097","author":[{"given":"Pierre","family":"Marquet","sequence":"first","affiliation":[{"name":"Pharmacology & Transplantation, Universit\u00e9 de Limoges, UMR1248 INSERM, Limoges, France; and"},{"name":"Department of Pharmacology and Toxicology, CHU Limoges, Limoges, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Labriffe","sequence":"additional","affiliation":[{"name":"Pharmacology & Transplantation, Universit\u00e9 de Limoges, UMR1248 INSERM, Limoges, France; and"},{"name":"Department of Pharmacology and Toxicology, CHU Limoges, Limoges, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Monchaud","sequence":"additional","affiliation":[{"name":"Pharmacology & Transplantation, Universit\u00e9 de Limoges, UMR1248 INSERM, Limoges, France; and"},{"name":"Department of Pharmacology and Toxicology, CHU Limoges, Limoges, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Picard","sequence":"additional","affiliation":[{"name":"Pharmacology & Transplantation, Universit\u00e9 de Limoges, UMR1248 INSERM, Limoges, France; and"},{"name":"Department of Pharmacology and Toxicology, CHU Limoges, Limoges, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Woillard","sequence":"additional","affiliation":[{"name":"Pharmacology & Transplantation, Universit\u00e9 de Limoges, UMR1248 INSERM, Limoges, France; and"},{"name":"Department of Pharmacology and Toxicology, CHU Limoges, Limoges, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"key":"R1-20261016","doi-asserted-by":"crossref","first-page":"115421","DOI":"10.1016\/j.addr.2024.115421","article-title":"Model-informed precision dosing: state of the art and future perspectives","volume":"215","author":"Minichmayr","year":"2024","journal-title":"Adv Drug Deliv Rev"},{"key":"R2-20261016","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/cpt.2202","article-title":"From therapeutic drug monitoring to model\u2010informed precision dosing for antibiotics","volume":"109","author":"Wicha","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"R3-20261016","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/FTD.0000000000001078","article-title":"Artificial Intelligence and machine learning approaches to facilitate therapeutic drug management and model-informed precision dosing","volume":"45","author":"Poweleit","year":"2023","journal-title":"Ther Drug Monit"},{"key":"R4-20261016","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/17512433.2025.2611431","article-title":"Optimized therapeutic drug monitoring: the role of machine learning models","volume":"19","author":"Sayadi","year":"2026","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R5-20261016","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cpt.2123","article-title":"Tacrolimus exposure prediction using machine learning","volume":"110","author":"Woillard","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"R6-20261016","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/cpt.2216","article-title":"Mycophenolic acid exposure prediction using machine learning","volume":"110","author":"Woillard","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"R8-20261016","doi-asserted-by":"crossref","first-page":"e1417","DOI":"10.1002\/wsbm.1417","article-title":"PharmGKB: a worldwide resource for pharmacogenomic information","volume":"10","author":"Barbarino","year":"2018","journal-title":"Wiley Interdiscipl Rev Syst Biol Med"},{"key":"R13-20261016","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0140-6736(22)01841-4","article-title":"A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study","volume":"401","author":"Swen","year":"2023","journal-title":"Lancet"},{"key":"R14-20261016","article-title":"BEST (Biomarkers, EndpointS, and Other Tools) Resource","year":"2016","journal-title":"Food and Drug Administration (US)"},{"key":"R15-20261016","year":"2026","journal-title":"US Food and Drug Administration"},{"key":"R17-20261016","doi-asserted-by":"crossref","first-page":"107627","DOI":"10.1016\/j.pharmthera.2020.107627","article-title":"Inflammation is a major regulator of drug metabolizing enzymes and transporters: consequences for the personalization of drug treatment","volume":"215","author":"Stanke-Labesque","year":"2020","journal-title":"Pharmacol Ther"},{"key":"R18-20261016","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","article-title":"Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions","volume":"14","author":"Roberts","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"R19-20261016","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/cpt.668","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics\u2010guided warfarin dosing: 2017 update","volume":"102","author":"Johnson","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"R20-20261016","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2022.9805","article-title":"Effect of pharmacogenomic testing for drug-gene interactions on medication selection and remission of symptoms in major depressive disorder: the PRIME care randomized clinical trial","volume":"328","author":"Oslin","year":"2022","journal-title":"JAMA"},{"key":"R21-20261016","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.911","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update","volume":"103","author":"Amstutz","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"R22-20261016","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1200\/JCO.2014.55.2307","article-title":"Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer","volume":"32","author":"Innocenti","year":"2014","journal-title":"J Clin Oncol"},{"key":"R23-20261016","doi-asserted-by":"crossref","first-page":"7984","DOI":"10.1038\/s41598-021-87095-0","article-title":"Association of genetic variants in TPMT, ITPA, and NUDT15 with azathioprine-induced myelosuppression in Southwest China patients with autoimmune hepatitis","volume":"11","author":"Miao","year":"2021","journal-title":"Sci Rep"},{"key":"R24-20261016","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1177\/1073110519876169","article-title":"Biomarker validation: context and complexities","volume":"47","author":"McShane","year":"2019","journal-title":"J L Med Ethics"},{"key":"R25-20261016","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1177\/1535370217739629","article-title":"Regulatory landscapes for biomarkers and diagnostic tests: qualification, approval, and role in clinical practice","volume":"243","author":"Mattes","year":"2018","journal-title":"Exp Biol Med"},{"key":"R26-20261016","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2217\/bmm-2020-0523","article-title":"Perspectives on statistical strategies for the regulatory biomarker qualification process","volume":"15","author":"Hendrix","year":"2021","journal-title":"Biomark Med"},{"key":"R27-20261016","doi-asserted-by":"crossref","first-page":"e70442","DOI":"10.1002\/pds.70442","article-title":"A pharmaco-epidemiological research program leveraging a nationwide database of kidney transplantation","volume":"35","author":"Marquet","year":"2026","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R28-20261016","doi-asserted-by":"crossref","first-page":"101481","DOI":"10.1016\/j.xcrm.2024.101481","article-title":"Federated machine learning in healthcare: a systematic review on clinical applications and technical architecture","volume":"5","author":"Teo","year":"2024","journal-title":"Cell Rep Med"},{"key":"R29-20261016","doi-asserted-by":"crossref","first-page":"100974","DOI":"10.1016\/j.patter.2024.100974","article-title":"Privacy preservation for federated learning in health care","volume":"5","author":"Pati","year":"2024","journal-title":"Patterns"},{"key":"R30-20261016","doi-asserted-by":"crossref","first-page":"712569","DOI":"10.3389\/fpubh.2021.712569","article-title":"Federated networks for distributed analysis of health data","volume":"9","author":"Hallock","year":"2021","journal-title":"Front Public Health"},{"key":"R31-20261016","doi-asserted-by":"crossref","DOI":"10.1101\/2025.01.29.25321214","article-title":"Federated prediction models and external validation for radiotherapy outcomes in oropharyngeal cancer using F.A.I.R. clinical and radiomics data","author":"Gouthamchand","year":"2025","journal-title":"Health Inform"},{"key":"R32-20261016","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41746-024-01359-3","article-title":"A scoping review of privacy and utility metrics in medical synthetic data","volume":"8","author":"Kaabachi","year":"2025","journal-title":"Npj Digit Med"},{"key":"R34-20261016","doi-asserted-by":"crossref","first-page":"105578","DOI":"10.1016\/j.phrs.2021.105578","article-title":"Estimation of drug exposure by machine learning based on simulations from published pharmacokinetic models: the example of tacrolimus","volume":"167","author":"Woillard","year":"2021","journal-title":"Pharmacol Res"},{"key":"R35-20261016","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.2147\/DDDT.S495050","article-title":"A real-time plasma concentration prediction model for voriconazole in elderly patients via machine learning combined with population pharmacokinetics","volume":"19","author":"Liu","year":"2025","journal-title":"Drug Des Devel Ther"},{"key":"R36-20261016","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1080\/17512433.2023.2226866","article-title":"Predicting busulfan exposure in patients undergoing hematopoietic stem cell transplantation using machine learning techniques","volume":"16","author":"Li","year":"2023","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R37-20261016","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/17512433.2023.2142561","article-title":"A model based on machine learning for the prediction of cyclosporin A trough concentration in Chinese allo-HSCT patients","volume":"16","author":"Song","year":"2023","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R38-20261016","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s11095-022-03252-8","article-title":"A machine learning approach to predict interdose vancomycin exposure","volume":"39","author":"Bououda","year":"2022","journal-title":"Pharm Res"},{"key":"R39-20261016","doi-asserted-by":"crossref","first-page":"1671652","DOI":"10.3389\/fphar.2025.1671652","article-title":"Precision dosing of voriconazole in immunocompromised children under 2 years: integrated machine learning and population pharmacokinetic modeling","volume":"16","author":"Shen","year":"2025","journal-title":"Front Pharmacol"},{"key":"R40-20261016","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s40262-023-01265-z","article-title":"Use of machine learning for dosage individualization of vancomycin in neonates","volume":"62","author":"Tang","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"R41-20261016","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s40262-022-01138-x","article-title":"A hybrid model associating population pharmacokinetics with machine learning: a case study with iohexol clearance estimation","volume":"61","author":"Destere","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"R42-20261016","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/FTD.0000000000001035","article-title":"Longitudinal exposure to tacrolimus and new-onset diabetes mellitus in renal transplant patients","volume":"45","author":"Destere","year":"2023","journal-title":"Ther Drug Monit"},{"key":"R43-20261016","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1111\/bcp.16368","article-title":"Cytochrome P450 phenotyping using the Geneva cocktail improves metabolic capacity prediction in a hospitalized patient population","volume":"91","author":"Gloor","year":"2025","journal-title":"Br J Clin Pharmacol"},{"key":"R44-20261016","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2217\/pgs.15.172","article-title":"CYP450 genotype and pharmacogenetic association studies: a critical appraisal","volume":"17","author":"Shah","year":"2016","journal-title":"Pharmacogenomics"},{"key":"R45-20261016","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/17425255.2022.2160317","article-title":"CYP2D6 pharmacogenetics and phenoconversion in personalized medicine","volume":"18","author":"Nahid","year":"2022","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R46-20261016","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/17425255.2025.2451440","article-title":"Pharmacogenetic guided drug therapy \u2013 how to deal with phenoconversion in polypharmacy","volume":"21","author":"Stingl","year":"2025","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R47-20261016","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2217\/pgs-2019-0134","article-title":"Pharmacogenomics at the center of precision medicine: challenges and perspective in an era of big data","volume":"21","author":"Primorac","year":"2020","journal-title":"Pharmacogenomics"},{"key":"R48-20261016","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/cpt.1651","article-title":"The clinical pharmacogenetics implementation consortium: 10 years later","volume":"107","author":"Relling","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"R49-20261016","doi-asserted-by":"crossref","first-page":"2200246","DOI":"10.1002\/bimj.202200246","article-title":"Biomarker\u2010based precision dose finding for immunotherapy combined with radiotherapy","volume":"65","author":"Lin","year":"2023","journal-title":"Biometrical J"},{"key":"R50-20261016","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/cpt.3197","article-title":"Beyond population\u2010level targets for drug concentrations: precision dosing needs individual\u2010level targets that include superior biomarkers of drug responses","volume":"116","author":"Polasek","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"R51-20261016","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1200\/CCI.20.00020","article-title":"Natural language processing to ascertain cancer outcomes from medical oncologist notes","volume":"4","author":"Kehl","year":"2020","journal-title":"JCO Clin Cancer Inform"},{"key":"R52-20261016","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/clpt.2013.47","article-title":"Pharmacovigilance using clinical notes","volume":"93","author":"LePendu","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"R53-20261016","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/jamia\/ocz166","article-title":"2018 n2c2 shared task on adverse drug events and medication extraction in electronic health records","volume":"27","author":"Henry","year":"2020","journal-title":"J Am Med Inform Assoc"},{"key":"R54-20261016","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/CCI.20.00139","article-title":"Automated NLP extraction of clinical rationale for treatment discontinuation in breast cancer","volume":"5","author":"Alkaitis","year":"2021","journal-title":"JCO Clin Cancer Inform"},{"key":"R55-20261016","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1136\/amiajnl-2012-000896","article-title":"Validation of electronic medical record-based phenotyping algorithms: results and lessons learned from the eMERGE network","volume":"20","author":"Newton","year":"2013","journal-title":"J Am Med Inform Assoc"},{"key":"R56-20261016","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/jamia\/ocv202","article-title":"PheKB: a catalog and workflow for creating electronic phenotype algorithms for transportability","volume":"23","author":"Kirby","year":"2016","journal-title":"J Am Med Inform Assoc"},{"key":"R57-20261016","first-page":"e85380","article-title":"Virtual patients in clinical trials for drug development: a narrative review","volume":"17","author":"Kleeberger","year":"2025","journal-title":"Cureus"},{"key":"R58-20261016","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41540-025-00592-0","article-title":"Enhancing randomized clinical trials with digital twins","volume":"11","author":"Akbarialiabad","year":"2025","journal-title":"Npj Syst Biol Appl"},{"key":"R59-20261016","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/s41591-024-02902-1","article-title":"Causal machine learning for predicting treatment outcomes","volume":"30","author":"Feuerriegel","year":"2024","journal-title":"Nat Med"},{"key":"R60-20261016","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.therap.2025.09.006","article-title":"Digital pharmacological twins: bridging multi-scale modelling and artificial intelligence for precision medicine: the DIGPHAT consortium","volume":"81","author":"Woillard","year":"2026","journal-title":"Therapie"},{"key":"R61-20261016","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1080\/17425255.2025.2501128","article-title":"Using validated model informed precision dosing for dose adjustment: superior evidence needed for efficacy and safety","volume":"21","author":"Jankovi\u0107","year":"2025","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R62-20261016","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/cpt.70090","article-title":"Electronic patient file-embedded model-informed precision dosing compared with physician dosing of tacrolimus in kidney transplantation","volume":"119","author":"Kuypers","year":"2026","journal-title":"Clin Pharmacol Ther"},{"key":"R63-20261016","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/bcp.12475","article-title":"Genotype\u2010guided drug prescribing: a systematic review and meta\u2010analysis of randomized control trials","volume":"80","author":"Goulding","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"R64-20261016","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available: table 1","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"key":"R65-20261016","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jclinepi.2019.02.004","article-title":"A systematic review shows no performance benefit of machine learning over logistic regression for clinical prediction models","volume":"110","author":"Christodoulou","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"R66-20261016","doi-asserted-by":"crossref","first-page":"m441","DOI":"10.1136\/bmj.m441","article-title":"Calculating the sample size required for developing a clinical prediction model","volume":"368","author":"Riley","year":"2020","journal-title":"BMJ"},{"key":"R67-20261016","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1056\/NEJMc2104626","article-title":"The clinician and dataset shift in artificial intelligence","volume":"385","author":"Finlayson","year":"2021","journal-title":"N Engl J Med"},{"key":"R68-20261016","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/s41591-019-0548-6","article-title":"Do no harm: a roadmap for responsible machine learning for health care","volume":"25","author":"Wiens","year":"2019","journal-title":"Nat Med"},{"key":"R69-20261016","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s42256-019-0048-x","article-title":"Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead","volume":"1","author":"Rudin","year":"2019","journal-title":"Nat Mach Intell"},{"key":"R70-20261016","doi-asserted-by":"crossref","first-page":"e745","DOI":"10.1016\/S2589-7500(21)00208-9","article-title":"The false hope of current approaches to explainable artificial intelligence in health care","volume":"3","author":"Ghassemi","year":"2021","journal-title":"Lancet Digit Health"},{"key":"R71-20261016","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1002\/sim.8296","article-title":"Assessment of heterogeneity in an individual participant data meta\u2010analysis of prediction models: an overview and illustration","volume":"38","author":"Steyerberg","year":"2019","journal-title":"Stat Med"},{"key":"R72-20261016","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/bimj.201900075","article-title":"Developing risk models for multicenter data using standard logistic regression produced suboptimal predictions: a simulation study","volume":"62","author":"Falconieri","year":"2020","journal-title":"Biom J"},{"key":"R73-20261016","doi-asserted-by":"crossref","first-page":"12598","DOI":"10.1038\/s41598-020-69250-1","article-title":"Federated learning in medicine: facilitating multi-institutional collaborations without sharing patient data","volume":"10","author":"Sheller","year":"2020","journal-title":"Sci Rep"},{"key":"R74-20261016","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/s41591-021-01506-3","article-title":"Federated learning for predicting clinical outcomes in patients with COVID-19","volume":"27","author":"Dayan","year":"2021","journal-title":"Nat Med"},{"key":"R75-20261016","first-page":"82","article-title":"To be or not to be, when synthetic data meet clinical pharmacology: a focused study on pharmacogenetics","volume":"14","author":"Woillard","year":"2025","journal-title":"CPT: Pharmacom Syst Pharmacol"},{"key":"R76-20261016","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41551-021-00751-8","article-title":"Synthetic data in machine learning for medicine and healthcare","volume":"5","author":"Chen","year":"2021","journal-title":"Nat Biomed Eng"},{"key":"R77-20261016","doi-asserted-by":"crossref","first-page":"k1479","DOI":"10.1136\/bmj.k1479","article-title":"Biases in electronic health record data due to processes within the healthcare system: retrospective observational study","volume":"361","author":"Agniel","year":"2018","journal-title":"BMJ"},{"key":"R78-20261016","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1126\/science.aax2342","article-title":"Dissecting racial bias in an algorithm used to manage the health of populations","volume":"366","author":"Obermeyer","year":"2019","journal-title":"Science"},{"key":"R79-20261016","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application","volume":"2","author":"Lund","year":"2015","journal-title":"Curr Epidemiol Rep"},{"key":"R80-20261016","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"R81-20261016","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/pds.5083","article-title":"Time-related biases in pharmacoepidemiology","volume":"29","author":"Suissa","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R82-20261016","doi-asserted-by":"crossref","first-page":"k3532","DOI":"10.1136\/bmj.k3532","article-title":"The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE)","volume":"363","author":"Langan","year":"2018","journal-title":"BMJ"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001534","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:00:24Z","timestamp":1792162824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":75,"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001534","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"2026-06-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}